Your browser doesn't support javascript.
loading
The detection of a strong episignature for Chung-Jansen syndrome, partially overlapping with Börjeson-Forssman-Lehmann and White-Kernohan syndromes.
Vos, Niels; Haghshenas, Sadegheh; van der Laan, Liselot; Russel, Perle K M; Rooney, Kathleen; Levy, Michael A; Relator, Raissa; Kerkhof, Jennifer; McConkey, Haley; Maas, Saskia M; Vissers, Lisenka E L M; de Vries, Bert B A; Pfundt, Rolph; Elting, Mariet W; van Hagen, Johanna M; Verbeek, Nienke E; Jongmans, Marjolijn C J; Lakeman, Phillis; Rumping, Lynne; Bosch, Danielle G M; Vitobello, Antonio; Thauvin-Robinet, Christel; Faivre, Laurence; Nambot, Sophie; Garde, Aurore; Willems, Marjolaine; Genevieve, David; Nicolas, Gaël; Busa, Tiffany; Toutain, Annick; Gérard, Marion; Bizaoui, Varoona; Isidor, Bertrand; Merla, Giuseppe; Accadia, Maria; Schwartz, Charles E; Ounap, Katrin; Hoffer, Mariëtte J V; Nezarati, Marjan M; van den Boogaard, Marie-José H; Tedder, Matthew L; Rogers, Curtis; Brusco, Alfredo; Ferrero, Giovanni B; Spodenkiewicz, Marta; Sidlow, Richard; Mussa, Alessandro; Trajkova, Slavica; McCann, Emma; Mroczkowski, Henry J.
Afiliação
  • Vos N; Amsterdam UMC, Department of Human Genetics, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
  • Haghshenas S; Amsterdam Reproduction & Development Research Institute, Amsterdam, The Netherlands.
  • van der Laan L; Verspeeten Clinical Genome Centre, London Health Sciences Centre, London, ON, N6A 5W9, Canada.
  • Russel PKM; Amsterdam UMC, Department of Human Genetics, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
  • Rooney K; Amsterdam Reproduction & Development Research Institute, Amsterdam, The Netherlands.
  • Levy MA; Amsterdam UMC, Department of Human Genetics, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
  • Relator R; Amsterdam Reproduction & Development Research Institute, Amsterdam, The Netherlands.
  • Kerkhof J; Verspeeten Clinical Genome Centre, London Health Sciences Centre, London, ON, N6A 5W9, Canada.
  • McConkey H; Department of Pathology and Laboratory Medicine, Western University, London, ON, N6A 3K7, Canada.
  • Maas SM; Verspeeten Clinical Genome Centre, London Health Sciences Centre, London, ON, N6A 5W9, Canada.
  • Vissers LELM; Verspeeten Clinical Genome Centre, London Health Sciences Centre, London, ON, N6A 5W9, Canada.
  • de Vries BBA; Verspeeten Clinical Genome Centre, London Health Sciences Centre, London, ON, N6A 5W9, Canada.
  • Pfundt R; Verspeeten Clinical Genome Centre, London Health Sciences Centre, London, ON, N6A 5W9, Canada.
  • Elting MW; Department of Pathology and Laboratory Medicine, Western University, London, ON, N6A 3K7, Canada.
  • van Hagen JM; Amsterdam UMC, Department of Human Genetics, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
  • Verbeek NE; Amsterdam Reproduction & Development Research Institute, Amsterdam, The Netherlands.
  • Jongmans MCJ; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands.
  • Lakeman P; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands.
  • Rumping L; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands.
  • Bosch DGM; Amsterdam UMC, Department of Human Genetics, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
  • Vitobello A; Amsterdam Reproduction & Development Research Institute, Amsterdam, The Netherlands.
  • Thauvin-Robinet C; Amsterdam UMC, Department of Human Genetics, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
  • Faivre L; Amsterdam Reproduction & Development Research Institute, Amsterdam, The Netherlands.
  • Nambot S; Department of Genetics, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
  • Garde A; Department of Genetics, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
  • Willems M; Amsterdam UMC, Department of Human Genetics, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
  • Genevieve D; Amsterdam Reproduction & Development Research Institute, Amsterdam, The Netherlands.
  • Nicolas G; Center for Medical Genetics, Antwerp University Hospital, University of Antwerp, Drie Eikenstraat 655, 2650, Edegem, Belgium.
  • Busa T; Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Toutain A; Université de Bourgogne, Inserm U1231, Equipe GAD, Dijon, France.
  • Gérard M; CHU Dijon Bourgogne, FHU-TRANSLAD, Unité Fonctionnelle Innovation en Diagnostic Génomique Des Maladies Rares, 21000, Dijon, France.
  • Bizaoui V; Université de Bourgogne, Inserm U1231, Equipe GAD, Dijon, France.
  • Isidor B; CHU Dijon Bourgogne, FHU-TRANSLAD, Unité Fonctionnelle Innovation en Diagnostic Génomique Des Maladies Rares, 21000, Dijon, France.
  • Merla G; CHU Dijon Bourgogne, Centre de Génétique, Centre de Référence Maladies Rares «Déficiences Intellectuelles de Causes Rares¼, FHU-TRANSLAD, Dijon, France.
  • Accadia M; Université de Bourgogne, Inserm U1231, Equipe GAD, Dijon, France.
  • Schwartz CE; CHU Dijon Bourgogne, Centre de Génétique, Centre de Référence Maladies Rares «Anomalies du Développement et Syndromes Malformatifs¼, FHU-TRANSLAD, Dijon, France.
  • Ounap K; Université de Bourgogne, Inserm U1231, Equipe GAD, Dijon, France.
  • Hoffer MJV; CHU Dijon Bourgogne, FHU-TRANSLAD, Unité Fonctionnelle Innovation en Diagnostic Génomique Des Maladies Rares, 21000, Dijon, France.
  • Nezarati MM; CHU Dijon Bourgogne, Centre de Génétique, Centre de Référence Maladies Rares «Anomalies du Développement et Syndromes Malformatifs¼, FHU-TRANSLAD, Dijon, France.
  • van den Boogaard MH; Université de Bourgogne, Inserm U1231, Equipe GAD, Dijon, France.
  • Tedder ML; CHU Dijon Bourgogne, Centre de Génétique, Centre de Référence Maladies Rares «Déficiences Intellectuelles de Causes Rares¼, FHU-TRANSLAD, Dijon, France.
  • Rogers C; INserm U1183, Department of Clinical Genetics, Montpellier University, 34090 CHU Montpellier, Montpellier, France.
  • Brusco A; INserm U1183, Department of Clinical Genetics, Montpellier University, 34090 CHU Montpellier, Montpellier, France.
  • Ferrero GB; Inserm U1245 and CHU Rouen, Department of Genetics and Reference Center for Developmental Disorders, Univ Rouen Normandie, 76000, Rouen, France.
  • Spodenkiewicz M; Department of Medical Genetics, Timone Hospital, Marseille, France.
  • Sidlow R; Genetics Department, University Hospital, UMR 1253, iBrain, University of Tours, Inserm, Tours, France.
  • Mussa A; APHP, Department of Genetics, Robert Debré Hospital, 75019, Paris, France.
  • Trajkova S; Clinical Genetics and Neurodevelopmental Disorders, Centre Hospitalier de L'Estran, 50170, Pontorson, France.
  • McCann E; Service de Génétique Médicale, CHU de Nantes, 44000, Nantes, France.
  • Mroczkowski HJ; Laboratory of Regulatory and Functional Genomics, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Foggia, Italy.
Hum Genet ; 143(6): 761-773, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38787418
ABSTRACT
Chung-Jansen syndrome is a neurodevelopmental disorder characterized by intellectual disability, behavioral problems, obesity and dysmorphic features. It is caused by pathogenic variants in the PHIP gene that encodes for the Pleckstrin homology domain-interacting protein, which is part of an epigenetic modifier protein complex. Therefore, we hypothesized that PHIP haploinsufficiency may impact genome-wide DNA methylation (DNAm). We assessed the DNAm profiles of affected individuals with pathogenic and likely pathogenic PHIP variants with Infinium Methylation EPIC arrays and report a specific and sensitive DNAm episignature biomarker for Chung-Jansen syndrome. In addition, we observed similarities between the methylation profile of Chung-Jansen syndrome and that of functionally related and clinically partially overlapping genetic disorders, White-Kernohan syndrome (caused by variants in DDB1 gene) and Börjeson-Forssman-Lehmann syndrome (caused by variants in PHF6 gene). Based on these observations we also proceeded to develop a common episignature biomarker for these disorders. These newly defined episignatures can be used as part of a multiclass episignature classifier for screening of affected individuals with rare disorders and interpretation of genetic variants of unknown clinical significance, and provide further insights into the common molecular pathophysiology of the clinically-related Chung-Jansen, Börjeson-Forssman-Lehmann and White-Kernohan syndromes.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Metilação de DNA / Deficiência Intelectual Limite: Child / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Metilação de DNA / Deficiência Intelectual Limite: Child / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article